Spots Global Cancer Trial Database for Safety of RAD001 in Combination With Cisplatin and Etoposide in Lung Cancer Patients
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Safety of RAD001 in Combination With Cisplatin and Etoposide in Lung Cancer Patients
Official Title: A Phase Ib Study Investigating the Combination of RAD001 With Cisplatin and Etoposide in Patients With Extensive-stage Small-cell Lung Cancer Not Previously Treated With Chemotherapy
Study ID: NCT00466466
Conditions
Interventions
Study Description
Brief Summary: This study aims to establish a tolerable dose level and regimen of RAD001 in combination with cisplatin and etoposide (standard-of-care chemotherapy) in patients with extensive stage small-cell lung cancer (SCLC) who have not previously been treated with systemic chemotherapy.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Highlands Oncology Group, Fayetteville, Arkansas, United States
University of Colorado Health Sciences Center, Aurora, Colorado, United States
Dana Faber Cancer Institute, Boston, Massachusetts, United States
MD Anderson Cancer Center, Houston, Texas, United States
Cancer Therapy and Research Center at UTHSCSA, San Antonio, Texas, United States
Novartis Investigative Site, Paris, , France
Contact Details
Name: Novartis Pharmaceuticals
Affiliation: Novartis Pharmaceuticals
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
